These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34473430)

  • 1. Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD-L1 and CTLA-4.
    Jiang C; Zhang L; Xu X; Qi M; Zhang J; He S; Tian Q; Song S
    Adv Sci (Weinh); 2021 Oct; 8(20):e2102500. PubMed ID: 34473430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced antitumor immune responses via a new agent [
    Jiang C; Tian Q; Xu X; Li P; He S; Chen J; Yao B; Zhang J; Yang Z; Song S
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):275-286. PubMed ID: 36242616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade.
    Dai X; Bu X; Gao Y; Guo J; Hu J; Jiang C; Zhang Z; Xu K; Duan J; He S; Zhang J; Wan L; Liu T; Zhou X; Hung MC; Freeman GJ; Wei W
    Mol Cell; 2021 Jun; 81(11):2317-2331.e6. PubMed ID: 33909988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade.
    Ma L; Gai J; Qiao P; Li Y; Li X; Zhu M; Li G; Wan Y
    Biochem Biophys Res Commun; 2020 Oct; 531(2):144-151. PubMed ID: 32782142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
    Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
    J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4.
    Zeng J; Fang Y; Zhang Z; Lv Z; Wang X; Huang Q; Tian Z; Li J; Xu W; Zhu W; Yu J; Liu T; Qian Q
    Oncogene; 2024 Jul; 43(29):2244-2252. PubMed ID: 38806619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model.
    Padrón Á; Hurez V; Gupta HB; Clark CA; Pandeswara SL; Yuan B; Svatek RS; Turk MJ; Drerup JM; Li R; Curiel TJ
    Exp Gerontol; 2018 May; 105():146-154. PubMed ID: 29326088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.
    Ma Y; Xue J; Zhao Y; Zhang Y; Huang Y; Yang Y; Fang W; Guo Y; Li Q; Ge X; Sun J; Zhang B; Zhang Y; Xiao J; Zhang L; Zhao H
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37263673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
    Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CTLA-4 antibody ipilimumab negatively affects CD4
    Rosskopf S; Leitner J; Zlabinger GJ; Steinberger P
    Cancer Immunol Immunother; 2019 Aug; 68(8):1359-1368. PubMed ID: 31332464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.
    Rozan C; Cornillon A; Pétiard C; Chartier M; Behar G; Boix C; Kerfelec B; Robert B; Pèlegrin A; Chames P; Teillaud JL; Baty D
    Mol Cancer Ther; 2013 Aug; 12(8):1481-91. PubMed ID: 23757164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy.
    Li T; Wang X; Niu M; Wang M; Zhou J; Wu K; Yi M
    Front Immunol; 2023; 14():1196970. PubMed ID: 37520520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities.
    Cui X; Jia H; Xin H; Zhang L; Chen S; Xia S; Li X; Xu W; Chen X; Feng Y; Wei X; Yu H; Wang Y; Zhan Y; Zhu X; Zhang X
    Front Immunol; 2021; 12():778978. PubMed ID: 34925354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
    Zhao Y; Lee CK; Lin CH; Gassen RB; Xu X; Huang Z; Xiao C; Bonorino C; Lu LF; Bui JD; Hui E
    Immunity; 2019 Dec; 51(6):1059-1073.e9. PubMed ID: 31757674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
    Kvarnhammar AM; Veitonmäki N; Hägerbrand K; Dahlman A; Smith KE; Fritzell S; von Schantz L; Thagesson M; Werchau D; Smedenfors K; Johansson M; Rosén A; Åberg I; Winnerstam M; Nyblom E; Barchan K; Furebring C; Norlén P; Ellmark P
    J Immunother Cancer; 2019 Apr; 7(1):103. PubMed ID: 30975201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.